Terns pharmaceuticals provides program updates and announces participation at td cowen 45th annual healthcare conference

Tern-701 cardinal study progressing well; dose expansion expected to initiate in 2q25 with additional safety and efficacy data in 4q25

COWN Ratings Summary

COWN Quant Ranking